Genmab A+s

Biontech Se

Joost J Neijssen

Janine Schuurman

Aran Frank Labrijn

Paul Parren

Joyce Meesters

Edward Norbert Van Den Brink

Bart De Goeij

Jan Van De Winkel

Patrick Van Berkel

Ewald T J Van Den Bremer

Tom Vink

Rene Hoet

Rik Rademaker

Arnout F Gerritsen

Isil Altintas

Michael J Gramer

Werner L Vos

Patrick Priem

Muriel Van Kampen

Amitava Kundu

Ugur Sahin

Friederike Gieseke

Alexander Muik

Esther Cornelia Wilhelmina Breij

Richard Hibbert

Bart-Jan De Kreuk

Sina Fellermeier-kopf

Lars Guelen

Rene M A Hoet

Jordan Blum

Patricia Garrido Castro

Ivan Kuzmanov

Claudia Paulmann

Karsten Beckmann

Ewald Van Den Bremer

Ewald Van Bremer

Edward Van Den Brink

Kristin Strumane

Joyce I Meesters

Ewald TJ Van Den Bremer

The present disclosure relates to antibodies having the ability to bind to the immune checkpoint protein programmed death-1 (PD-1), such as human PD-1, or nucleic acids encoding such antibodies, wherein the antibodies comprise modifications in the Fc region eliminating or reducing a Fc-mediated effector function of the antibodies. The present disclosure also relates to compositions or kits comprising said antibodies or nucleic acids, as well as to the use of these antibodies or nucleic acids or compositions in the field of medicine, preferably in the field of immunotherapy, e.g., for the treatment of cancers. The present invention further relates to methods for inducing an immune response in a subject comprising providing to the subject an antibody of the present disclosure or one or more nucleic acids encoding such an antibody, or a composition comprising said antibody or nucleic acids.

Monoclonal antibodies directed against programmed death-1 protein and their use in medicine

Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins.

Heterodimeric antibody Fc-containing proteins and methods for production thereof

The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

Humanized or chimeric CD3 antibodies

Bispecific antibodies which comprise one antigen-binding region binding to an epitope of human epidermal growth factor receptor 2 (HER2) and one antigen-binding region binding to human CD3, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods for preparing and using the antibodies are also disclosed.

Bispecific antibodies against HER2 and CD3

Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

Monoclonal antibodies against c-Met

The present invention relates to an in vitro method for production of heterodimeric proteins.

Production of heterodimeric proteins

Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.

Inert format

Heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins.

Growing community of inventors

Werkhoven, Netherlands

Joost J Neijssen